Reduction of Liver Span and Parameters of Inflammation in Nonalcoholic Fatty Liver Disease Patients Treated with Lycosome Formulation of Phosphatidylcholine: A Preliminary Report

Table 2

Liver span parameters after treatment with regular and lycosome formulations of PC (medians with 95/5%% CI).

Duration of treatment	Formulations of PC
	Regular	Lycosome
	Mid-Clavicular size (cm)
Baseline	16.1 (16.8/15.1)	16.0 (17.1/15.5)
1 month	16.0 (16.8/14.7)	15.7 (17.2/15.0)
2 months	15.6 (16.4/14.5)	15.1 (17.2/14.4)
	Mid-Sternal size (cm)
Baseline	7.2 (7.7/6.5)	7.2 (7.5/6.9)
1 month	7.1 (7.57/6.2)	7.0 (7.5/6.2)
2 months	7.0 (7.3/6.2)	6.8 (7.2/6.5)

The patients were screened, enrolled, randomized, and treated with regular (PC) or lycosome (PC-Lycosome) formulations of phosphatidylcholine (PC) for 2 months as described in Materials and Methods. Median values with confidence intervals for Mid-Clavicular and Mid-Sternal liver size at time “0” and the end point of the study are shown above; as compared to baseline.